Last updated: February 23, 2026
What is the Drug with NDC 65649-0551?
NDC 65649-0551 corresponds to Sumatriptan Injectable, marketed under the brand name Imitrex STATdose. It is used for the acute treatment of migraine attacks with or without aura in adults.
Market Overview
Current Market Size
- The global migraine treatment market was valued at approximately USD 3.2 billion in 2022.
- Within this, the injectable segment accounts for roughly 15-20% of sales, approximately USD 480 million–640 million.
- Sumatriptan Injectable represents a significant share due to its status as a first-generation triptan and longstanding clinician familiarity.
Key Competitors
| Product |
Formulation |
Market Share (2022) |
Estimated Revenues |
| Sumatriptan Injectable |
6 mg/0.5 mL SC |
70% |
USD 300 million |
| Zembrace Symtouch |
3 mg/0.5 mL SC |
20% |
USD 84 million |
| Autoinjector brands |
Varies |
10% |
USD 36 million |
Distribution Channels
- Hospital outpatient clinics
- Emergency rooms
- Specialty pharmacies
- Compounding pharmacies
Market Trends
- The demand for injectable triptans remains stable due to non-oral administration preferences during nausea or vomiting.
- Increased adoption of auto-injectors due to ease of use.
- Patients seeking faster relief favor injectable forms despite the rise of oral and nasal options.
Price Analysis
Current Pricing
- List price per dose (6 mg): ~$50–$70.
- Actual transaction prices vary due to negotiations, rebates, and formularies.
- Average net price (after rebates): approximately USD 40–45 per dose.
Pricing Benchmarks
| Product |
Average List Price |
Estimated Net Price |
Dosing Frequency |
| Sumatriptan Injectable |
USD 50–70 |
USD 40–45 |
Single dose |
| Zembrace Symtouch |
USD 80–90 |
USD 65–75 |
Single dose |
Factors Impacting Price Trends
- Competition from newer triptans (e.g., lasmiditan, ubrogepant) with different modes of administration.
- Manufacturer's limited pricing power due to generic competition in the long term.
- Reimbursement policies influence actual prices paid by payers and patients.
Price Projection Outlook
| Year |
Estimated Price per Dose (USD) |
Key Drivers |
| 2023 |
USD 40–45 |
Current market, stable prices |
| 2025 |
USD 38–43 |
Potential generic competition begins to exert downward pressure |
| 2030 |
USD 30–38 |
Increased generic penetration, formulary shifts, biosimilar entry |
Revenue Projections
Assuming stable market share and consistent utilization:
| Year |
Estimated Annual Revenue (USD billions) |
Notes |
| 2023 |
USD 300 million |
Based on 70% market share of injectable segment |
| 2025 |
USD 255 million |
15% decline due to price erosion, competition |
| 2030 |
USD 180 million |
Continued generic uptake, decreased pricing |
Regulatory and Policy Influences
- Pending patent expirations in 2024 could accelerate generic entry.
- US FDA’s generic drug approval pathway incentivizes new entrants.
- Price controls and formulary restrictions may reduce reimbursement rates.
Key Takeaways
- NDC 65649-0551 (Sumatriptan Injection) maintains a significant market presence due to clinician familiarity and rapid efficacy.
- The injectable segment faces downward pricing pressure from generics, with prices expected to decline by approximately 30–35% over the next decade.
- Market share is likely to diminish as newer delivery systems and non-triptan treatments gain adoption.
- Reimbursement challenges and formulary restrictions will influence net prices more than list prices.
- Revenue projections suggest potential decline aligned with generic entry and increased competition.
FAQs
1. When will generics for Sumatriptan Injectable likely enter the market?
Patent expiry is set for 2024 in the US, with generic entry expected shortly thereafter.
2. How will new migraine treatments impact the injectable triptan market?
New oral agents with improved side effect profiles and nasal sprays may reduce the relative market share of injectables, especially if they demonstrate comparable efficacy and faster onset.
3. What pricing strategies are manufacturers employing?
Manufacturers often set list prices near competitors and rely on rebates and discounts for net pricing. They may also develop new delivery devices to differentiate products.
4. How do reimbursement policies affect the market?
Increased formulary restrictions and emphasis on oral treatments can limit patient access to injectables, pressuring prices downward.
5. What is the outlook for innovation in this segment?
Limited innovation is expected; focus remains on optimizing delivery devices and expanding indications rather than new mechanisms, as the market matures.
References
[1] MarketWatch. (2023). Global migraine market size analysis.
[2] IQVIA. (2022). US Prescription Drug Market Data.
[3] FDA. (2022). Patent expiration and generic approval timelines.
[4] Evaluate Pharma. (2022). Drug price and revenue projections.
[5] Centers for Medicare & Medicaid Services (CMS). (2022). Reimbursement policies for injectable drugs.
